Companies › Vasgene Therapeutics
1 active drug program in 3 registered trials: 2 Phase 2, 1 Phase 1; Oncology; next expected readout Sep 2029.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| SEphB4-HSA Ephrin-B2 inhibitor | EFNB2 | Phase 2 | Muscle-Invasive Bladder Carcinoma; Stage IV Bladder Urothelial Carcinoma; Head and Neck Squamous Cell Carcinoma | Sep 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT02495896 | SEphB4-HSA | Phase 1 | Head and Neck Squamous Cell Carcinoma | Oncology | Dec 2026 |
| NCT02717156 | SEphB4-HSA | Phase 2 | Stage IV Bladder Urothelial Carcinoma | Oncology | Dec 2027 |
| NCT06493552 | SEphB4-HSA | Phase 2 | Muscle-Invasive Bladder Carcinoma | Oncology | Sep 2029 |
Suzhou BlueHorse Therapeutics Pieris Pharmaceuticals Evaxion Biotech Primmune Therapeutics Tessa Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.